SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists

Abbott Laboratories (New York Stock Exchange:ABT)

US · Delayed Price · Currency is USD
105.25-0.27 (-0.26%)
 
Market Cap182.12B-18.6%
Revenue (ttm)46.59B+8.1%
Net Income5.42B-61.2%
EPS3.11-61.0%
Shares Out1.73B
PE Ratio33.84
Forward PE17.35
Dividend$2.48(2.36%)
Ex-Dividend DateJul 15, 2026
Volume6,386,483
Open105.69
Previous Close105.52
Day's Range104.79 - 106.85
52-Week Range81.97 - 137.49
Beta0.59
AnalystsBuy
Price Target123.64(+17.47%)
Earnings DateOct 21, 2026
-0.28% (1D)
No price history available.

About ABT

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Address
100 Abbott Park Road, Abbott Park, IL, 60064-6400, US
Market Cap
182.12 billion
Employees
115,000
Industrial Classification
Medical - Devices

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$46.85M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-0.26%
5 Days
-2.65%
1 Month
-3.10%
6 Months
-4.79%
1 Year
-18.64%

$ABT stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of ABT by members of U.S. Congress

PoliticianTypeTraded
Rich McCormickHouse / RSale$1.00K – $15.00KJul 30, 2026
Mike KellyHouse / RSale$1.00K – $15.00KJul 17, 2026
Mike KellyHouse / RSale$1.00K – $15.00KJul 16, 2026
Rick W. AllenHouse / RSale$15.00K – $50.00KJul 14, 2026
Richard W. AllenHouse / RSale$15.00K – $50.00KJul 14, 2026
Rick W. AllenHouse / RSale$15.00K – $50.00KJul 13, 2026
Rich McCormickHouse / RPurchase$1.00K – $15.00KJun 12, 2026
Rick W. AllenHouse / RSale$15.00K – $50.00KApr 15, 2026

Recently reported changes in ABT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ABT's directors and management

Net Shares Purchased by Insiders−500k−250k02025Q32025Q42026Q12026Q22026Q3

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ABT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ABT Revenue by Segment or Geography

$12.59BTotal
SegmentRevenue% of All
Medical Devices$5.85B46.48%
Diagnostic Products$3.09B24.55%
Nutritional Products$2.14B17.03%
Established Pharmaceutical Products$1.50B11.90%
Other$5.00M0.04%

As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ABT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ABT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ABT

ETFEst. Holding Size
VTIVanguard Morningstar Total Stock Market ETF$5.86B
SCHDSchwab U.S. Dividend Equity ETF$5.08B
VOOVanguard S&P 500 ETF$4.83B
IVViShares Core S&P 500 ETF$2.48B
SPYState Street SPDR S&P 500 ETF$2.26B
VTVVanguard Morningstar Value ETF$1.75B

Estimated from each fund’s disclosed top holdings × AUM

ABT Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

Members only

The live Insider Score for ABT is included with Insider Access.

Unlock Insider Score

Bull Case vs Bear Case

AI-generated from ABT’s recent data — informational, not investment advice

Generating analysis…

Insider Score

Our 0–100 Insider Score and the signals behind it.

Members only

The live Insider Score and its full factor breakdown are included with Insider Access.

Unlock Insider Score

Recent Insider Activity

Buys
0
Sells
4
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.